The landscape of metastatic breast cancer (MBC) research is currently undergoing a period of profound transformation, marked by a surge in scientific inquiry, shifting regulatory paradigms, and a burgeoning demand for patient-centered clinical trial designs. At the heart of this movement is METAvivor, a non-profit organization dedicated to funding research for stage IV breast cancer. In a recent comprehensive update, METAvivor President Kelly Shanahan, M.D., detailed the organization’s current initiatives, the critical state of research funding, and the evolving therapeutic landscape that offers new hope to those living with a terminal diagnosis.
Main Facts: A Pivot Point for Metastatic Research
The primary focus of recent efforts within the MBC community centers on the critical need for sustained research funding and the integration of the patient voice into the highest levels of oncology discourse. Dr. Shanahan, a physician living with MBC, highlights a significant uptick in interest from the scientific community. During the current grant cycle, METAvivor’s Scientific Advisory Board (SAB) received 200 Letters of Intent (LOIs)—a 100% increase over historical averages for the second consecutive year.
This surge is not merely a sign of scientific curiosity but a symptom of broader instability in federal research funding. As traditional sources like the National Institutes of Health (NIH) face budgetary uncertainties, private organizations like METAvivor have become essential lifelines for researchers focusing specifically on metastasis—the process by which cancer spreads, which is responsible for nearly all breast cancer deaths.
Simultaneously, the regulatory environment is seeing a flurry of activity. In May alone, the U.S. Food and Drug Administration (FDA) issued several landmark approvals and expanded indications for drugs targeting specific genetic mutations and subtypes, including ESR1-mutated ER+/HER2- cancer and triple-negative breast cancer (TNBC). These developments coincide with major international conferences, such as the American Society of Clinical Oncology (ASCO) Annual Meeting, where the focus is shifting toward "patient-centered endpoints"—measures of success in clinical trials that prioritize the quality of life and the lived experience of the patient.
Chronology: A Season of High-Stakes Advocacy
The late spring and early summer months represent a dense calendar of events that shape the future of MBC treatment.
May: Grant Reviews and Regulatory Milestones
The month began with the METAvivor SAB meeting to vet the 200 LOIs submitted for this year’s grant cycle. This rigorous screening process is the first step in identifying the most "exciting and impactful" ideas that will eventually receive funding. Concurrent with these administrative efforts, the FDA accelerated the therapeutic pipeline by approving vepdegestrant (Veppanu) and datopotamab deruxtecan (Datroway), while expanding the use of trastuzumab deruxtecan (Enhertu).
Late May to Early June: The ASCO Annual Meeting
As May concludes, the oncology world converges on Chicago for the ASCO Annual Meeting. Dr. Shanahan’s participation in a session titled “Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials” marks a pivotal moment for patient advocacy. Her presentation, scheduled for May 31, advocates for a radical redesign of clinical trials, urging researchers to consult patients—the "experts in living with the disease"—during the design phase rather than as an afterthought.
Mid-June: Global Scientific Collaboration
Following ASCO, the focus shifts to Minnesota for the Hormel Institute’s Global Cancer Consortium. This meeting emphasizes the biological mechanisms of metastasis. Keynote speaker Dr. Danny Welch, a founding member of METAvivor’s SAB, will present on the "hallmarks of metastasis," providing the scientific foundation upon which new therapies are built.
Supporting Data: The Rising Tide of Innovation
The data emerging from recent clinical trials and the sheer volume of research interest underscore a significant momentum in the field.
The Funding Gap
The 200 LOIs received by METAvivor represent a diverse array of scientific inquiries, ranging from immunotherapy to the targeting of dormant cancer cells. According to Dr. Stuart Martin, a long-time member of the SAB, the organization is "doing outstanding work to help metastasis research keep moving forward during this especially challenging time for research." The doubling of applications highlights a "funding cliff" where many high-quality projects may go unfunded without private intervention.
Breakthrough Therapeutics
The recent FDA approvals are backed by robust clinical data:
- Vepdegestrant (Veppanu): A proteolysis-targeting chimera (PROTAC) estrogen receptor degrader. It specifically targets the ESR1 mutation, which frequently develops as a resistance mechanism in patients previously treated with aromatase inhibitors.
- Datopotamab Deruxtecan (Datroway): An antibody-drug conjugate (ADC) targeting TROP2. It has shown significant efficacy in patients with metastatic TNBC who are not candidates for immunotherapy, a group that historically had very limited options.
- Trastuzumab Deruxtecan (Enhertu): The expansion into early-stage HER2+ settings aims to utilize the drug’s potent "bystander effect" to eradicate micro-metastases before they can progress to incurable stage IV disease.
Official Responses: Divergence in Regulatory Philosophies
A central point of discussion within the MBC community is the recent discrepancy between American and European regulatory bodies regarding the drug camizestrant.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) recently voted against recommending the approval of switching patients from an aromatase inhibitor (AI) and CDK4/6 inhibitor to camizestrant (a next-generation SERD) plus a CDK4/6 inhibitor upon the detection of an ESR1 mutation—before radiographic evidence of progression. The committee expressed concerns about whether changing treatment based on molecular markers alone, rather than visible tumor growth, provides a clear survival benefit.
In contrast, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval based on the SERENA-6 trial data. This divergence has sparked a debate on how "new technology," such as liquid biopsies that detect circulating tumor DNA (ctDNA), should be incorporated into regulatory decisions.
METAvivor board members, including Dr. Shanahan, Janice Cowden, and Lynda Weatherby, have been vocal in their critique of the ODAC decision. Through platforms like the Live from Stage 4 podcast, they argue that waiting for a tumor to grow large enough to be seen on a scan before changing a failing treatment is a "reactive" rather than "proactive" approach that may cost patients valuable time.
Implications: Redefining the "Bigger Table"
The current trajectory of MBC advocacy and research carries profound implications for the future of oncology.
The Professionalization of Patient Advocacy
The inclusion of Patient Advocate Reviewers (PARs) in the grant-review process signifies a shift in how scientific merit is measured. By requiring that grants be reviewed not just for scientific rigor but for "patient impact," METAvivor is ensuring that funded research aligns with the actual needs of the community—such as reducing toxicity and extending progression-free survival.
The Shift Toward Proactive Treatment
The ongoing review of camizestrant and the rise of ctDNA monitoring suggest a future where MBC is managed more like a chronic disease, with treatment adjustments made at the molecular level. If the FDA eventually aligns with the EMA’s perspective, it could herald a new era of "precision monitoring" where clinicians stay one step ahead of mutational resistance.
The Economic Urgency
Dr. Shanahan’s call for donations serves as a stark reminder of the economic realities of cancer research. While pharmaceutical companies fund late-stage clinical trials, the "high-risk, high-reward" basic research into the mechanisms of metastasis often falls to non-profits. The success of the 200 LOIs depends entirely on the availability of private capital, making public engagement and philanthropy more critical than ever.
A Personal and Professional Intersection
The narrative of Dr. Kelly Shanahan herself—a doctor who treated patients and is now a patient on a clinical trial awaiting her own scans—encapsulates the urgency of the moment. Her dual perspective lends a unique authority to the demand for a "bigger table" in oncology. As she prepares to speak at ASCO and the Hormel Institute, the message is clear: the most effective way to design meaningful trials and discover life-saving treatments is to involve those whose lives depend on the results.
The coming months will be telling. As ASCO concludes and the full grant applications are reviewed, the MBC community remains in a state of "exhilarating exhaustion," balanced between the fear of a changing diagnosis and the hope provided by an unprecedented wave of scientific innovation.
About the Author
